HENGRUI PHARMA (01276) Receives Clinical Trial Approval from China's NMPA for HRS-6093 Tablets

Stock News

Aug 25, 2025

HENGRUI PHARMA (01276) announced that it has recently received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for HRS-6093 tablets, with clinical trials expected to commence shortly.

HRS-6093 tablets represent a novel, highly efficient, and selective oral KRAS G12D inhibitor that specifically binds to the KRAS G12D mutant protein to deliver anti-tumor effects. According to the company's research, no similar products have received market approval globally to date.

As of now, the cumulative research and development investment for the HRS-6093 tablets project totals approximately 29.84 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1135409847"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135409847\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135409847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135409847","market":"sg","top_or_hot":-1,"title":"HENGRUI PHARMA (01276) Receives Clinical Trial Approval from China's NMPA for HRS-6093 Tablets","media":"Stock News","content":"<p>HENGRUI PHARMA (01276) announced that it has recently received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for HRS-6093 tablets, with clinical trials expected to commence shortly.</p>\n<p>HRS-6093 tablets represent a novel, highly efficient, and selective oral KRAS G12D inhibitor that specifically binds to the KRAS G12D mutant protein to deliver anti-tumor effects. According to the company's research, no similar products have received market approval globally to date.</p>\n<p>As of now, the cumulative research and development investment for the HRS-6093 tablets project totals approximately 29.84 million yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA (01276) Receives Clinical Trial Approval from China's NMPA for HRS-6093 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA (01276) Receives Clinical Trial Approval from China's NMPA for HRS-6093 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-25 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (01276) announced that it has recently received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for HRS-6093 tablets, with clinical trials expected to commence shortly.</p>\n<p>HRS-6093 tablets represent a novel, highly efficient, and selective oral KRAS G12D inhibitor that specifically binds to the KRAS G12D mutant protein to deliver anti-tumor effects. According to the company's research, no similar products have received market approval globally to date.</p>\n<p>As of now, the cumulative research and development investment for the HRS-6093 tablets project totals approximately 29.84 million yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1135409847","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135409847","pubTimestamp":1756113975,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) announced that it has recently received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for HRS-6093 tablets, with clinical trials...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0239":"医药制造","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0183":"MSCI概念","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0028":"国家队","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1191":"制药","01276":"恒瑞医药","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0060":"抗癌","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC"},"translate_title":"恒瑞医药(01276)HRS-6093片剂获中国NMPA临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA (01276) announced that it has recently received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for HRS-6093 tablets, with clinical trials expected to commence shortly.\nHRS-6093 tablets represent a novel, highly efficient, and selective oral KRAS G12D inhibitor that specifically binds to the KRAS G12D mutant protein to deliver anti-tumor effects. According to the company's research, no similar products have received market approval globally to date.\nAs of now, the cumulative research and development investment for the HRS-6093 tablets project totals approximately 29.84 million yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}